Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
Amrubicin has shown single-agent activity in lung cancer. The combination of cyclophosphamide
and anthracyclines has been studied and concluded that the combination was tolerable, could
be given safely, and therapeutically useful.
This Phase I study will evaluate the combination of cyclophosphamide with amrubicin in
relapsed solid tumors and will define the MTD of the combination in a US population.
Phase:
Phase 1
Details
Lead Sponsor:
Lawrence Einhorn
Collaborators:
Celgene Corporation Hoosier Cancer Research Network